一般市民のコロナワクチン接種、１１月にも準備完了予定　中国

【北京ＡＦＰ＝時事】中国が開発する新型コロナウイルスワクチンの一般市民への投与は、早ければ11月にも準備が整うことが、関係者の話で分かった。各社がワクチン臨床試験の最終段階に入っており、開発競争は世界で過熱している。（写真は資料写真）
　ワクチン開発を進める中国のシノバック・バイオテックと中国医薬集団総公司（シノファーム）の担当者らは共に、第３相臨床試験の終了後、年末にも自社ワクチンが承認される予定だとＡＦＰに話していた。
　そして１４日夜、中国疾病対策予防センター（ＣＣＤＣ）のバイオセーフティー首席専門家は国営中国中央テレビ（ＣＣＴＶ）の取材に対し、「１１月か１２月ごろ」には一般市民のワクチン接種が可能になる予定だと述べた。
　この専門家は「第３相臨床試験の結果を踏まえると、現在の進展状況は非常に順調」だと述べ、自身も４月にワクチンを接種したがこれまでのところ体調は良好だと話した。
　中国で開発中のワクチン候補のうち一部は、緊急措置として社会の機能維持に必要不可欠な仕事に従事する人にすでに投与されている。【翻訳編集ＡＦＰＢＢＮｅｗｓ】
〔ＡＦＰ＝時事〕（2020/09/17-12:09）

A China-developed coronavirus vaccine could be ready for the public as early as November, a Chinese official has told state television, as the global race to clear the final round of trials heats up.
Chinese manufacturers have been bullish about development, with companies Sinovac Biotech and Sinopharm even putting their vaccine candidates on display at a trade fair in Beijing this month.
Representatives of the firms told AFP that they hope their vaccines will be approved after phase 3 trials as early as year-end.
And on late Monday, the chief biosafety expert at the Chinese Centre for Disease Control told state broadcaster CCTV that a vaccine would be available to the general public around November or December.
Wu Guizhen did not specify which vaccine she was referring to, but said based on the phase 3 clinical results, the current progress is very smooth.
Wu added that she had taken a vaccine in April and has felt good over the past few months, although she did not specify which candidate she had taken.
There are currently nine vaccine candidates in late-stage human trials, although some have hit recent obstacles -- pharma giant AstraZeneca and Oxford University momentarily paused clinical trials last week after a volunteer developed an unexplained illness.
Some of China's vaccine candidates have already been offered to essential workers under an emergency use programme.
A Sinovac spokesman told AFP this month that tens of thousands of people had voluntarily taken its vaccine, including 90 percent of its employees and their families -- between 2,000 and 3,000 people.
In June, China's military approved a vaccine for use within its ranks developed by its research unit and a biotech firm.